Corvus Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2018 Annual Meeting of Stockholders held by Corvus Pharmaceuticals, Inc. on June 21, 2018. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
As of the record date (April 25, 2018), there were 29,193,690 shares of common stock outstanding. A total of 26,419,920 shares were voted on the following proposals:
- Proposal 1: Election of Directors
- Steve E. Krognes: 20,020,111 votes For; 5,226,255 votes Withheld; 1,173,554 Broker Non-Votes.
- Scott W. Morrison: 24,862,897 votes For; 383,469 votes Withheld; 1,173,554 Broker Non-Votes.
- Proposal 2: Ratification of Independent Registered Accounting Firm
- PricewaterhouseCoopers LLC: 24,455,773 votes For; 5,603 votes Against; 1,958,544 Abstain.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management commentary on future outlook, specific risks, contingencies, or unusual items. The document serves solely to disclose the tabulation of stockholder votes.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (29,193,690) and the percentage of shares voted (approximately 90.5%).
- Note the significant number of votes withheld for director nominee Steve E. Krognes (5,226,255) compared to Scott W. Morrison (383,469).
- Confirm the ratification of PricewaterhouseCoopers LLC as the independent auditor for the fiscal year ending December 31, 2018.
- Review the Definitive Proxy Statement on Schedule 14A filed on April 27, 2018, for detailed background on the director nominees and proposals.